Naslov
ENADA/NADH improves cognitive impairment of Alzheimer patients

Autori
Demarin, Vida ; Podobnik Šarkanji, Slava ; Storga Tomić, Daniela ; Kay, G. ; Martinić Popović, Irena ; Bosnar Puretić, Marijana ; Birkmayer J.G.D.

Izvornik
Journal of tumor marker oncology (0886-3849) 18 (2002); 43-45

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
ENADA/NADH; Alzheimer disease

Sažetak
Alzheimer's disease (AD) represents 45% of the total cumulative dementias. Although significant progress has been achieved in revealing the etiology of AD, the search for efficient therapy stays the main goal. Nicotinamide Adenine Dinucleotide (NADH) is biologically identified as a cofactor necessary for a number of cellular actions, such as energy production, cell regulation and DNA repair, enhancement of cellular immune system, repairment from oxidative damage. NADH is thought to be reduced in patients with degenerative disorders ; in clinical trials NADH has been shown to improve cognitive functioning in patients with AD, Parkinson's disease as well as in Chronic fatigue syndrome. The exact mechanism of action of NADH needs to be yet established. In this double blind, placebo-controlled parallel group pilot study the aim was to establish weather NADH would improve cognitive functioning in patients with AD. Subjects (48) were paired matched on the basis of initial severity of dementia using the Mini Mental state Examination Scale (MMSE) and age. Subjects were randomized to receive either ENADAINADH 5 mg tablets per day or matching placebo tablets over a period of six months. Subjects were monitored at monthy intervals. The following neuropsychological test batteries were used: MMSE, Mattis Dementia Rating Scale (MDRS), Hopkins Verbal Learning Test (HVLT), Verbal fluency Test (VF), Fuld Object Memory Test (FOMT) and CogScreenTM Matching to Sample Test (MTS). After 6 months, patients receiving NADH compared to placebo group have shown to improve on VF test (p=0.056). Evaluating the NADH patients according to MDRS, improvement has been shown by 2.8 points and placebo group deteriorated by 4.9 points ; 15 out of 21 pairs improved in NADH group compared to placebo. The NADH has not shown significant improvement on the HVLT. In conclusion, subjects receiving NADH have shown improvement on measures of MDRS and VF, furthermore, several subjects also shown clinical improvement in cognitive functioning. ENADA/NADH was tolerated well and was not associated with adverse effects. These results are encouraging ; ENADAINADH is a safe medication that improves cognitive impairment in patients with AD.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA